Introduction
Akums Drugs and Pharmaceuticals Limited, a prominent name in the pharmaceutical industry, is set to launch its Initial Public Offering (IPO). This guide provides an in-depth look into the details of the IPO, including its structure, timeline, and key financial metrics.
🗓️ IPO Schedule
- Opens: July 30, 2024
- Closes: August 1, 2024
- Basis of Allotment: August 2, 2024
- Initiation of Refunds: August 5, 2024
- Credit of Shares to Demat: August 5, 2024
- Listing Date: August 6, 2024
📊 Issue Breakdown
- Total Issue Size: 27,345,162 shares (₹1,856.74 Cr)
- Fresh Issue: 10,014,727 shares (₹680.00 Cr)
- Offer for Sale: 17,330,435 shares (₹1,176.74 Cr)
IPO Details
- Face Value: ₹2 per share
- Price Band: ₹646 to ₹679 per share
- Lot Size: 22 Shares
Reservation
- QIB Shares Offered: Not less than 75% of the Net Offer
- Retail Shares Offered: Not more than 10% of the Offer
- NII (HNI) Shares Offered: Not less than 15% of the Offer
Lot Size
Investors can bid for a minimum of 22 shares and in multiples thereof. Below is the minimum and maximum investment by retail investors and HNIs:
- Retail (Min): 1 lot (22 shares) = ₹14,938
- Retail (Max): 13 lots (286 shares) = ₹194,194
- S-HNI (Min): 14 lots (308 shares) = ₹209,132
- S-HNI (Max): 66 lots (1,452 shares) = ₹985,908
- B-HNI (Min): 67 lots (1,474 shares) = ₹1,000,846
💼 Company Overview
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. The company specializes in product development, manufacturing, R&D of formulations, regulatory dossier preparation, and testing services. Additionally, Akums manufactures branded drugs and active pharmaceutical ingredients (APIs).
Key Features
- Product Range: Tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, gummy bears, etc.
- Manufacturing Facilities: 10 units with a cumulative capacity of 49.21 billion units annually (as of September 30, 2023).
- Expansion Plans: Two additional units for CDMO business to be commissioned in FY 2025.
- Certifications: EU-GMP, WHO-GMP, US NSF.
Employee Overview
As of September 30, 2023, Akums employed 16,463 people, including 7,211 full-time employees and 9,252 contract employees.
💹 Financial Performance
Financial Information (Restated Consolidated)
- Revenue Growth: 13.81% (FY 2024 vs FY 2023)
- Profit After Tax (PAT): Dropped by -99.19% (FY 2024 vs FY 2023)
Key Financial Metrics (in ₹ Crore)
| Period Ended |
31 Mar 2024 |
31 Mar 2023 |
31 Mar 2022 |
| Assets |
3,516.37 |
3,266.53 |
3,069.05 |
| Revenue |
4,212.21 |
3,700.93 |
3,694.52 |
| Profit After Tax |
0.79 |
97.82 |
-250.87 |
| Net Worth |
709.50 |
717.19 |
621.98 |
| Reserves and Surplus |
861.01 |
868.70 |
787.79 |
| Total Borrowing |
491.56 |
536.97 |
357.95 |
Key Performance Indicators (KPI)
- ROE: 0.11%
- ROCE: 3.37%
- Debt/Equity: 0.69
- RoNW: -0.57
- P/BV: 13.69
- PAT Margin: 0.02%
📈 Akums Drugs and Pharmaceuticals IPO Promoter Holding
- Pre Issue: 84.94%
- Post Issue: [Not specified]
🏢 Book Running Lead Managers and Registrar
- Lead Managers: ICICI Securities Limited, Axis Bank Limited, Citigroup Global Markets India Private Limited, Ambit Private Limited
- Registrar: Link Intime India Private Ltd
🏢 Objects of the Issue
- Repayment/Prepayment of indebtedness of the company and its subsidiaries
- Funding incremental working capital requirements
- Pursuing inorganic growth initiatives through acquisitions
- General corporate purposes
This IPO presents an opportunity for investors to become part of Akums Drugs and Pharmaceuticals Limited, a company with a strong foundation and significant growth potential in the pharmaceutical industry.